EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal lead

Jiasi Hao iD, Behrooz Z Alizadeh iD, Maarten J Postma iD, Daan J Touw iD, Stephan J L Bakker iD, Lisa A de Jong

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0319022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Jiasi Hao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Kidney Transplantation, Chelation Therapy, Lead, Succimer. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma, Netherlands, Chiesi Pharmaceuticals BV, Ministerie van Economische Zaken en Klimaat.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kidney transplant recipients (KTR) with high-normal lead have a higher risk of graft failure (GF). Clinically, chelation therapy using meso-2,3-dimercaptosuccinic acid (DMSA) removes lead. Despite the proposal that chelation therapy can prevent GF through lead removal, evidence is lacking. To guide research efforts, we conducted an early economic evaluation, aiming to explore the economic feasibility of screening for and implementing chelation therapy with oral DMSA for high-normal plasma lead concentrations in KTR (i.e., the intervention) compared to standard of care.

Methods

A Markov model simulated the life course of 10,000 KTR in the Netherlands from a societal perspective. Transition probabilities were estimated using the data from TransplantLines Food and Nutrition Biobank and Cohort study. Costs and utilities were sourced from publications and public data. Model robustness was investigated through deterministic and probabilistic sensitivity analyses. Various administration strategies were tested. Five-year costs were calculated from a healthcare payer’s perspective. Value of information was assessed.

Results

The intervention was cost-saving and improved health, leading to a dominant incremental cost-effectiveness ratio. The result was most sensitive to transition probabilities (led by GF, followed by death with functioning graft and after graft failure). The probability of the intervention being cost-effective was 60%. Chelation strategies did not affect the result. The intervention applied to the Dutch KTR population could save €27 million in the initial five years. Further research is desirable if the cost of obtaining perfect information on GF survival is approximately below €4,000/KTR (all uncertainties under €5,000/KTR).

Conclusion

The cost-effectiveness of the intervention is robust in KTR, except when considering the uncertainties around (graft) survival probabilities. Applying chelation therapy in the new setting we studied holds significant potential. However, trials that systematically assess the efficacy, administration strategies, and impacts on survival are crucial in updating the current evaluation and informing policies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationChelation TherapyLeadSuccimerChelating AgentsHumansCost-Benefit AnalysisMarkov ChainsNetherlandsTransplant RecipientsMaleFemale

Substanzen

LeadSuccimerChelating Agents

Autor:innen und Institutionen

  • Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Economics, Econometrics and Finance, Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands.
  • Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

ORCID-Profile: Jiasi Hao, Behrooz Z Alizadeh, Maarten J Postma, Daan J Touw, Stephan J L Bakker

Förderung

  • Astellas Pharma, Netherlands
  • Chiesi Pharmaceuticals BV
  • Ministerie van Economische Zaken en Klimaat

Zitieren

APA

Hao, J., Alizadeh, B. Z., Postma, M. J., Touw, D. J., Bakker, S. J. L., & de Jong, L. A. (2025). Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal lead. PLOS ONE. https://doi.org/10.1371/journal.pone.0319022

Vancouver

Hao J, Alizadeh BZ, Postma MJ, Touw DJ, Bakker SJL, de Jong LA. Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal lead. PLOS ONE. 2025. doi:10.1371/journal.pone.0319022

BibTeX
@article{Hao2025,
  author = {Hao, Jiasi and Alizadeh, Behrooz Z and Postma, Maarten J and Touw, Daan J and Bakker, Stephan J L and de Jong, Lisa A},
  title = {Early economic evaluation of chelation therapy in kidney transplant recipients with high-normal lead},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0319022}
}
Kostenlos starten →